Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria

被引:36
作者
Sayed-Ahmed, MM
Shouman, SA
Rezk, BM
Khalifa, MH
Osman, AMM
El-Merzabania, MM
机构
[1] Natl Canc Inst, Dept Canc Biol, Pharmacol Unit, Cairo, Egypt
[2] Cairo Univ, Fac Sci, Dept Zool, Cairo, Egypt
关键词
adriamycin; beta-oxidation; cardiotoxicity; propionyl-L-carnitine;
D O I
10.1006/phrs.1999.0583
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Propionyl-L-carnitine (PLC), a natural short-chain derivative of L-carnitine, has been tested in this study as a potential protective agent against adriamycin (ADR)-induced cardiotoxicity in isolated rat heart myocytes and mitochondria. In cardiac myocytes, ADR (0.5 mM) caused a significant (70%) inhibition of palmitate oxidation, whereas, PLC (5 mM) induced a significant (49%) stimulation. Addition of PLC to ADR-incubated myocytes induced 79% reversal of ADR-induced inhibition of palmitate oxidation. In isolated rat heart mitochondrial ADR produced concentration-dependent inhibition of both palmitoyl-CoA and palmitoyl-carnitine oxidation, while PLC caused a more than 2.5-fold increase in both substrates. Preincubation of mitochondria with 5 mM PLC caused complete reversal of ADR-induced inhibition in the oxidation of both substrates. Also ADR induced concentration-dependent inhibition of CPT I which is parallel to the inhibition of its substrate palmitoyl-CoA. In rat heart slices, ADR induced a significant (65%) decrease in adenosine triphosphate (ATP) and this effect is reduced to 17% only by PLC. Results of this study revealed that ADR induced its cardiotoxicity by inhibition of CPT I and beta-oxidation of long-chain fatty acids with the consequent depletion of ATP in cardiac tissues, and that PLC can be used as a protective agent against ADR-induced cardiotoxicity. (C) 2000 Academic Press.
引用
收藏
页码:143 / 150
页数:8
相关论文
共 32 条
[1]   Regulation of fatty acid oxidation by acetyl-CoA generated from glucose utilization in isolated myocytes [J].
Abdelaleem, S ;
Nada, MA ;
SayedAhmed, M ;
Hendrickson, SC ;
StLouis, J ;
Walthall, HP ;
Lowe, JE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1996, 28 (05) :825-833
[2]   Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes [J].
AbdelAleem, S ;
ElMerzabani, MM ;
SayedAhmed, M ;
Taylor, DA ;
Lowe, JE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (02) :789-797
[3]  
Al-Shabanah O, 1998, BIOCHEM MOL BIOL INT, V45, P419
[4]   PREVENTION OF DOXORUBICIN-INDUCED MYOCARDIAL AND HEMATOLOGICAL TOXICITIES IN RATS BY THE IRON CHELATOR DESFERRIOXAMINE [J].
ALHARBI, MM ;
ALGHARABLY, NM ;
ALSHABANAH, OA ;
ALBEKAIRI, AM ;
OSMAN, AMM ;
TAWFIK, HN .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 (03) :200-204
[5]   INTERACTION OF CARNITINE WITH MITOCHONDRIAL CARDIOLIPIN [J].
BATTELLI, D ;
BELLEI, M ;
ARRIGONIMARTELLI, E ;
MUSCATELLO, U ;
BOBYLEVA, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1117 (01) :33-36
[6]   ALTERATIONS IN FATTY-ACID METABOLISM IN ADRIAMYCIN CARDIOMYOPATHY [J].
BEANLANDS, RSB ;
SHAIKH, NA ;
WEN, WH ;
DAWOOD, F ;
UGNAT, AM ;
MCLAUGHLIN, PR ;
CARERE, R ;
LIU, PP .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1994, 26 (01) :109-119
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   HEPATIC AND CARDIAC CARNITINE PALMITOYLTRANSFERASE ACTIVITY - EFFECTS OF ADRIAMYCIN AND GALACTOSAMINE [J].
BRADY, LJ ;
BRADY, PS .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (20) :3419-3423
[9]  
BUZADAR AV, 1985, CANCER, V55, P2761
[10]   ADRIAMYCIN - REVIEW [J].
CARTER, SK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 55 (06) :1265-1274